Ipamorelin: a selective growth hormone secretagogue

Ipamorelin is a synthetic peptide from the growth-hormone-releasing peptide (GHRP) family. It is best known for being selective — a quality that has made it one of the most studied secretagogues in laboratory research.

What "selective" means here

Growth hormone secretagogues can prompt the pituitary to release growth hormone, but some earlier peptides also nudged other hormones such as cortisol or prolactin. In the research literature ipamorelin is described as more selective: in study models it engages the growth-hormone secretagogue receptor with comparatively little effect on those other pathways. That cleaner profile is why researchers value it as a tool.

A different receptor from GHRH analogues

Ipamorelin does not act on the GHRH receptor. It works through the growth-hormone secretagogue receptor (the ghrelin receptor), a separate signalling route. This is why it is often studied side by side with GHRH analogues such as tesamorelin or CJC-1295 — the two families approach the growth-hormone axis from different angles. Our overview of growth hormone secretagogues explains the distinction.

Why the combination is studied

Because GHRH analogues and GHRPs act on different receptors, researchers frequently examine them together to understand how the two signals interact at the pituitary in laboratory models. Ipamorelin's selectivity makes it a useful, well-defined half of that comparison.

Form and documentation

Ipamorelin is supplied as a lyophilised powder and reconstituted with bacteriostatic water before use; every Vela order includes a free 3 mL bacteriostatic water vial, and the on-site reconstitution simulator helps you plan the dilution. Each batch ships with a certificate of analysis issued within six months of sale.